Abstract：
UNASSIGNED: This study assesses the effectiveness and safety of using Ologen implants (Aeon Astron Europe BV, Leiden, The Netherlands) as an adjunctive therapy in childhood glaucoma surgeries.
UNASSIGNED: We systematically reviewed the existing literature across various electronic databases to examine the effectiveness and safety of Ologen implants in childhood glaucoma surgeries.
UNASSIGNED: Our analysis encompassed 14 studies on the use of Ologen implants in childhood glaucoma. Among these, seven were prospective, five were retrospective, and two did not specify their study design. Success rates varied depending on the type of surgery and the included childhood glaucoma subtype. The success rates for Ologen implants-augmented surgeries were as follows: 33.3-70% for trabeculectomy, 50-81% for combined trabeculotomy-trabeculectomy procedure, 33%-87% for glaucoma drainage device, and 60% in deep sclerectomy.
UNASSIGNED: Ologen implant has a potential role in mitigating postoperative fibrosis and enhancing success rates in various childhood glaucoma surgeries. However, the existing literature is limited. Future comparative prospective studies with larger cohorts are needed.
UNASSIGNED: We systematically reviewed the existing literature across various electronic databases to examine the effectiveness and safety of Ologen implants in childhood glaucoma surgeries.
UNASSIGNED: Our analysis encompassed 14 studies on the use of Ologen implants in childhood glaucoma. Among these, seven were prospective, five were retrospective, and two did not specify their study design. Success rates varied depending on the type of surgery and the included childhood glaucoma subtype. The success rates for Ologen implants-augmented surgeries were as follows: 33.3-70% for trabeculectomy, 50-81% for combined trabeculotomy-trabeculectomy procedure, 33%-87% for glaucoma drainage device, and 60% in deep sclerectomy.
UNASSIGNED: Ologen implant has a potential role in mitigating postoperative fibrosis and enhancing success rates in various childhood glaucoma surgeries. However, the existing literature is limited. Future comparative prospective studies with larger cohorts are needed.
摘要：
■本研究评估了使用Ologen植入物的有效性和安全性（AeonAstronEuropeBV，莱顿,荷兰）作为儿童青光眼手术的辅助疗法。
■我们系统地回顾了各种电子数据库中的现有文献，以检查Ologen植入物在儿童青光眼手术中的有效性和安全性。
■我们的分析包括14项关于在儿童青光眼中使用Ologen植入物的研究。其中,七个是潜在的，五个是回顾性的，两人没有具体说明他们的研究设计。成功率取决于手术类型和包括的儿童青光眼亚型。Ologen植入增强手术的成功率如下：小梁切除术的成功率为33.3-70％，小梁切开-小梁切除术联合手术占50-81%，33％-87％用于青光眼引流装置，深层巩膜切除术占60%。
■Ologen植入物在减轻术后纤维化和提高各种儿童青光眼手术成功率方面具有潜在作用。然而,现有的文献是有限的。未来需要更大队列的比较前瞻性研究。
■我们系统地回顾了各种电子数据库中的现有文献，以检查Ologen植入物在儿童青光眼手术中的有效性和安全性。
■我们的分析包括14项关于在儿童青光眼中使用Ologen植入物的研究。其中,七个是潜在的，五个是回顾性的，两人没有具体说明他们的研究设计。成功率取决于手术类型和包括的儿童青光眼亚型。Ologen植入增强手术的成功率如下：小梁切除术的成功率为33.3-70％，小梁切开-小梁切除术联合手术占50-81%，33％-87％用于青光眼引流装置，深层巩膜切除术占60%。
■Ologen植入物在减轻术后纤维化和提高各种儿童青光眼手术成功率方面具有潜在作用。然而,现有的文献是有限的。未来需要更大队列的比较前瞻性研究。
